🎄 Season’s Greetings from Quantoom Biosciences! 🎄 As 2024 comes to a close, we want to express our heartfelt gratitude for your trust, collaboration, and support throughout the year. Together, we’ve achieved remarkable milestones and set the stage for an exciting future. ✨ As we welcome 2025, let’s look forward to new opportunities, strengthened partnerships, and continued growth. May this new year bring inspiration, innovation, and shared success for us all. From everyone at Quantoom Biosciences, we wish you a joyful holiday season and a brilliant start to 2025! 🎁 Warm regards, The Quantoom Team
About us
Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (Nfinity™) that encompasses DNA (Nplify™) and RNA (Ntensify™) manufacturing and formulation (Ncapsulate™), along with critical reagent supply, from sequence to large-scale production. We are a team of scientists, engineers, and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. Quantoom Biosciences is part of Univercells, a global life sciences Group with the mission of making biologics accessible to all.
- Website
-
http://www.quantoom.com
External link for Quantoom Biosciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Nivelles, Walloon Region
- Type
- Privately Held
- Specialties
- Synthetic biology, DNA, RNA, RNAplatform, Nucleic acids, Bioproduction, Vaccines, and Therapeutics
Locations
-
Primary
Rue de la Maîtrise 11
Nivelles, Walloon Region 1400, BE
-
Rue du Pelvoux 6-18
Batiment Vanoise
Évry-Courcouronnes, Île-de-France 91080, FR
Employees at Quantoom Biosciences
Updates
-
✨ 2024: A Year of Groundbreaking Achievements with Our Partners! ✨ This year has been truly exceptional. As a full-stack RNA technology partner, we have continued to push boundaries, delivering remarkable results through our design platform, Ntensify® production technology, and proprietary formulations. We owe our success to the incredible trust and collaboration of our partners, who have been instrumental in driving innovation and impact. A heartfelt thank you to: • Monika Ślęzak - European Vaccine Initiative (EVI) • Irina Meln, PhD - European Vaccine Initiative • David Torres - CER Groupe • Emilien Nicolas - CER groupe • Bryan Charleston - The Pirbright Institute • Julian Seago - The Pirbright Institute • Jorge Emilio Osorio - VaxThera • Juan Pablo Hernandez Ortiz - Vaxthera • Erwin Camacho Burgos - Vaxthera Together, we are shaping the future of RNA technology and making a meaningful difference. Here’s to even greater innovation and success in the years to come! 🚀 #mRNAPlatform #RNAVaccines #Partnerships #mRNAProduction
-
[A word from our CEO] As the year end approaches, I’d like to celebrate this incredible year. 2024 has been the first full year of commercialization of our Ntensify® technology. The 20 first implementations of this year wouldn’t have been possible without the trust and spirit of collaboration from our early adopters. Today, let’s take the opportunity to thank these essential partners. As we continue to evolve and expand our capabilities, they may rest assured that their early commitment remains the cornerstone of our success. Together, we're preparing for the next health crisis and concretely shaping a healthier, more secure future for everyone! Mauricio Zuma Medeiros - Bio-Manguinhos Ricardo de Godoi Mattos Ferreira - Bio-Manguinhos Patrícia Neves - Bio-Manguinhos Ana Paula Dinis Ano Bom - Bio-Manguinhos Mario Moreira - Fiocruz Haroldo Cid da Silva Junior - Bio-Manguinhos Daniele Ramos Rocha - Bio-Manguinhos Maria do Carmo Gonçalves da Rocha - Bio-Manguinhos Pascale Delcomminette - AWEX Brent Van Tassel - Advisor to His Majesty the King Dirk Wouters - BE Official Petro Terblanche - Afrigen Biologics Caryn Fenner - Afrigen Biologics Andre Choo - A*STAR Huibin Zhang - A*STAR Boon Tong Koh - A*STAR Sze Woei Ng - A*STAR Duccio Medini, PhD - Wellcome Leap Umesh Shaligram - Serum Institute of India Dr. Mangesh Joshi - Serum Institute of India Amar Shrivastava - Serum Institute of India Jorge Emilio Osorio- Vaxthera Juan Pablo Hernandez Ortiz - Vaxthera Erwin Camacho Burgos - Vaxthera Adriansjah Azhari - BioFarma Neni Nurainy - BioFarma indra rudiansyah - BioFarma Amadou Sall - Institut Pasteur Dakar Sène Marie-Angélique - Institut Pasteur Dakar Joe Fitchett- Institut Pasteur Dakar Makram Essafi - Institut Pasteur Tunis Sinda ZARROUK - Institut Pasteur Tunis Fernando Lobos - Sinergium German Sanchez Alberti - Sinergium Dr. Morena Makhoana - Biovac Ebrahim Mohamed - Biovac Danie Wilsenach - Biovac Mohammad Mainul Ahasan - Incepta Pharmaceuticals Imran Khan - Incepta Pharmaceuticals Abdul Muktadir - Incepta Pharmaceuticals Mahbubul Karim - Incepta Pharmaceuticals Cedric Volanti - Exothera Bernard Sagaert - Etherna Prof. Kiat Ruxrungtham - Chula VRC
-
Recap of an Eventful Week at the Belgian Economic Mission to Brazil 🇧🇪🇧🇷 The Belgian Economic Mission to Brazil (22 Nov. - 1 Dec.) was a week full of remarkable moments for UNIVERCELLS and Quantoom Biosciences represented by Jose Castillo and Maria Davila-Saignol, but two key events on Friday, November 29, stood out as highlights: ✨ Private Meeting with HRH Princess Astrid: We were honored to participate in a special session to present the details of the agreement signed between Bio-Manguinhos / Fiocruz, Univercells and Quantoom Biosciences. This successful partnership is a testament to the strength of Belgium-Brazil collaboration, focusing on RNA-based therapies and local biopharma capacity building. ➠ Read the press release: https://shorturl.at/k6QiZ In addition to HRH Princess Astrid, notable attendees included: • HE Dirk Wouters , Ambassador of Belgium in Washington DC • HE Peter Claes, Ambassador of Belgium in Brazil • Pascale Delcomminette, CEO of AWEX • Caroline Mouchart, Belgian Consul General in Rio de Janeiro • Brent Van Tassel, Economic Advisor to his Majesty the King • Mario Moreira, President of Fiocruz • Mauricio Zuma, CEO of Bio-Manguinhos • Ricardo de Godoi Mattos Ferreira, Vice Director of Innovation at BioManguihnos • Patrícia Neves, Scientific Leader and Project Manager - HUBRNA • Rodrigo dos SANTOS A. GARCIA, Economic and Commercial Counselor at AWEX • Fabienne L'Hoost, Director General at Belgian Foreign Trade Agency ✨ Seminar on Epidemics and Vaccine Resilience: During this seminar on “The Future of Epidemics and the Future of Vaccines,” Jose Castillo presented on “Scalable and Integrated mRNA Vaccine Manufacturing: Endemic Facility with Pandemic Resilience.” The session emphasized our vision for sustainable and innovative vaccine production systems, critical for future health challenges. Other highlights from the mission included a warm kick-off in São Paulo, engaging meetings with Brazil’s Vice President Geraldo Alckmin, collaborative discussions at Hospital Albert Einstein, and the signing of a Memorandum of Understanding in Rio de Janeiro, marking a milestone in Belgium-Brazil biotech collaboration. ✨ Special Thanks: A heartfelt thank you to Wallonia Export & Investment Agency, Wallonie Bruxelles International, Embaixada Do Reino da Bélgica no Brasil, Consulado Geral da Bélgica, Consulado Geral da Bélgica no Rio de Janeiro, and Bio-Manguinhos / Fiocruz for their outstanding organization and coordination throughout this inspiring mission. 🌍 Together, we are shaping the future of health innovation! #BEmissionBRA #BiotechInnovation #PartneringForGlobalHealth #BelgiumBrazilRelations #HealthcareInnovation
-
+2
-
🌍 PRESS RELEASE: Belgium and Brazil Join Forces to Advance RNA-Based Therapies! We are delighted to announce that a Memorandum of Understanding (MoU) was signed yesterday in Rio De Janeiro between Bio-Manguinhos / Fiocruz, Quantoom Biosciences, and UNIVERCELLS, in the presence of HRH Princess Astrid of Belgium, during an official signing ceremony as part of the Belgian Economic Mission to Brazil 🇧🇪🇧🇷. This significant agreement was signed by Jose Castillo, CEO of Quantoom Biosciences, and Mauricio Zuma, CEO of Bio-Manguinhos, and represents a commitment to: 🔬 Develop next-generation saRNA vaccines for global and regional impact. 🤝 Co-create RNA-based therapies targeting critical diseases like cancer. 🌍 Explore One Health applications, addressing the interconnection between human, animal, and environmental health. 🏭 Establish an mRNA manufacturing facility in Brazil to strengthen regional biopharma capabilities. This partnership exemplifies the power of international collaboration in addressing global health challenges, combining expertise to expand access to innovative health solutions. 📢 Learn more about this transformative partnership: https://shorturl.at/k6QiZ #BiotechInnovation #PartneringForGlobalHealth #BEmissionBRA
-
Exciting Updates from the Belgian Economic Mission in Brazil! 🇧🇪🇧🇷 UNIVERCELLS and Quantoom Biosciences were honored to have Jose Castillo and Maria Davila-Saignol representing both companies during an official meeting in São Paulo with Her Royal Highness Princess Astrid of Belgium and His Excellency Geraldo Alckmin, Vice President of Brazil. This special gathering, held last Tuesday, provided an opportunity for selected CEOs from Belgian companies to present their innovations and expertise—a proud moment for all participants! The same day, we were thrilled to engage in a dynamic B2B pitching session at the renowned Hospital Albert Einstein (HIAE) in São Paulo. This inspiring event brought together key stakeholders in healthcare and biotech for meaningful discussions and potential collaborations. 🤝 A heartfelt thank you to Dr. Miguel Cendoroglo Neto (HIAE, CMO), Dr. Caroline Kanaan (Medical Lead,HIAE), Dr. Vanessa Teich (Director of Oncology and Hematology), Dr. Eliézer Silva (COO, HIAE), Xavier Hormaechea (Managing Director, UCB Belgium, Head of EU Corporate Affairs), Michel Conte (Country Lead at UCB Brazil), Laurent Bernard (Inward Investment Manager at AWEX), and Rodrigo dos SANTOS A. GARCIA (Economic and Commercial Counselor at AWEX) for the warm hospitality and the exceptional organization 🙏 This mission underscores the power of international cooperation, innovation, and shared vision. 🌍✨ #BEmissionBRA #Innovation #BelgiumBrazilRelations #HealthcareInnovation
-
A fantastic start to the Belgian Economic Mission in Brazil, chaired by Her Royal Highness Princess Astrid of Belgium, representing His Majesty the King, and accompanied by our esteemed ministers Hadja Lahbib, Pierre-Yves Jeholet, Matthias Diependaele, and Rudi Vervoort. We’re proud to share that UNIVERCELLS and Quantoom Biosciences are part of this prestigious delegation. Both companies are represented by Jose Castillo, CEO of Quantoom Biosciences and co-founder of Univercells, and Maria Davila-Saignol, Director Global South for Univercells and Quantoom Biosciences. Please see the pictures from the opening event organized by the Embassy of Belgium and the Consulate General in São Paulo, where the delegation was warmly welcomed by: - HE Peter Claes, Ambassador of Belgium in Brazil, - Valentine Mangez, Belgian Consul General in São Paulo, - Caroline Mouchart, Belgian Consul General in Rio de Janeiro, - Claudia Rolim, Economic and Commercial Counselor at FIT, - Rodrigo dos SANTOS A. GARCIA, Economic and Commercial Counselor at AWEX, and - Dieter Poleyn, Economic and Commercial Counselor at hub.brussels. - Emmanuel De Groof, Consul in Rio de Janeiro We’re also delighted to share moments from yesterday morning’s panel discussion on “The challenges of universal access to quality healthcare in Brazil,” where Jose Castillo contributed to the discussion on vaccines. Looking forward to more fruitful discussions and collaborations throughout the mission! #BEmissionBRA
-
🚀 Discover our mRNA production system for clinical trials and commercial manufacturing! The Ntensify® midi is a GMP-grade mRNA production system introducing a novel approach to mRNA synthesis and purification. Both steps are automated in a single equipment to enable scalable production of 1 to 5 g per batch. Follow this link to discover more about the Ntensify midi: https://lnkd.in/em5Qq_Ka #RNAProduction #AutomatedEquipment #ClinicalTrials #CommercialManufacturing
-
Quantoom Biosciences reposted this
Reinventing mRNA production with Quantoom. Meet them in this webinar we organised! 🧬 #Biotechnology #Vaccines #MRNA #Innovation #Syngoi #Quantoom
-
✅ Last week, Quantoom Biosciences had an incredible time at the International mRNA Health Conference in Boston! 🌍✨ A big thank you to everyone who visited us at our booth and connected with our team. 🤝💡 It was inspiring to share insights and discuss how Quantoom Biosciences is shaping the future of mRNA technology. Our CEO’s talk, Jose Castillo, was a standout moment, showcasing our bold vision and innovative solutions! 🎤🚀 🎉 A special shoutout to the winners of our contest who took home a custom lab set to build our Ntensify® midi with LEGO® bricks! 🏆 Missed us at the event and want to learn more about our technologies? Feel free to reach out to us at [email protected]—we’d love to connect! 💬 #QuantoomBiosciences #mRNAInnovation #LifeSciences #Networking